Elliot Chartash

7.3k total citations · 3 hit papers
49 papers, 4.7k citations indexed

About

Elliot Chartash is a scholar working on Immunology, Oncology and Rheumatology. According to data from OpenAlex, Elliot Chartash has authored 49 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 22 papers in Oncology and 14 papers in Rheumatology. Recurrent topics in Elliot Chartash's work include Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (11 papers) and Immunotherapy and Immune Responses (9 papers). Elliot Chartash is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (11 papers) and Immunotherapy and Immune Responses (9 papers). Elliot Chartash collaborates with scholars based in United States, Israel and Australia. Elliot Chartash's co-authors include Steven Fischkoff, Edward Keystone, Daniel E. Furst, C. Birbara, Michael E. Weinblatt, Michael H. Weisman, Larry W. Moreland, Leah Teoh, Hua Ye and H Tannenbaum and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Elliot Chartash

47 papers receiving 4.6k citations

Hit Papers

Adalimumab, a fully human... 2003 2026 2010 2018 2003 2004 2021 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    2003 1.4k citations Michael E. Weinblatt, Edward Keystone et al. Arthritis & Rheumatism profile →
  2. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
    2004 956 citations Edward Keystone, Steven Fischkoff et al. Arthritis & Rheumatism profile →
  3. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Elliot Chartash 3.0k 1.5k 1.4k 792 601 49 4.7k
Andrea Rubbert‐Roth 3.3k 1.1× 1.5k 1.0× 1.7k 1.2× 647 0.8× 885 1.5× 123 5.1k
Maria Greenwald 2.7k 0.9× 1.2k 0.8× 1.5k 1.0× 1.2k 1.5× 868 1.4× 76 5.1k
Xavier Le Loët 3.3k 1.1× 1.3k 0.9× 1.4k 1.0× 328 0.4× 644 1.1× 198 5.4k
Hans‐Peter Tony 1.6k 0.6× 803 0.5× 2.1k 1.5× 866 1.1× 660 1.1× 151 4.4k
Alain Cantagrel 5.3k 1.8× 1.9k 1.2× 2.0k 1.4× 625 0.8× 861 1.4× 202 7.5k
C. Birbara 3.8k 1.3× 1.8k 1.2× 1.9k 1.4× 351 0.4× 531 0.9× 43 5.5k
Raimón Sanmartí 3.6k 1.2× 1.3k 0.8× 1.6k 1.1× 338 0.4× 416 0.7× 263 5.3k
Emma Alecock 2.4k 0.8× 1.2k 0.8× 965 0.7× 570 0.7× 510 0.8× 9 3.6k
Alejandro Balsa 3.3k 1.1× 920 0.6× 2.4k 1.7× 664 0.8× 596 1.0× 285 6.1k
Hideto Kameda 2.6k 0.9× 1.2k 0.8× 1.2k 0.8× 398 0.5× 631 1.0× 196 4.3k

Countries citing papers authored by Elliot Chartash

Since Specialization
Citations

This map shows the geographic impact of Elliot Chartash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliot Chartash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliot Chartash more than expected).

Fields of papers citing papers by Elliot Chartash

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elliot Chartash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliot Chartash. The network helps show where Elliot Chartash may publish in the future.

Co-authorship network of co-authors of Elliot Chartash

This figure shows the co-authorship network connecting the top 25 collaborators of Elliot Chartash. A scholar is included among the top collaborators of Elliot Chartash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliot Chartash. Elliot Chartash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Niu, Jiaxin, Corinne Maurice‐Dror, D.H. Lee, et al.. (2021). First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Annals of Oncology. 33(2). 169–180. 196 indexed citations breakdown →
4.
Papadopoulos, Kyriakos P., Karen A. Autio, Talia Golan, et al.. (2020). Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. Clinical Cancer Research. 27(7). 1904–1911. 46 indexed citations
5.
Ahn, M-J., Jiaxin Niu, Dongwook Kim, et al.. (2020). 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Annals of Oncology. 31. S887–S887. 26 indexed citations
6.
Niu, Jiaxin, Adnan Nagrial, Mark Voskoboynik, et al.. (2020). 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC. Annals of Oncology. 31. S891–S892. 19 indexed citations
7.
Middleton, Mark R., Martin Wermke, Emílio Calvo, et al.. (2018). Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors. Annals of Oncology. 29. viii712–viii712. 20 indexed citations
8.
Ribas, Antoni, René González, Joseph J. Drabick, et al.. (2016). Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma. Annals of Oncology. 27. vi365–vi365. 5 indexed citations
9.
Kivitz, Alan, Joy Schechtman, Michele Texter, et al.. (2014). Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial. The Journal of Rheumatology. 41(4). 648–657. 51 indexed citations
10.
Torrance, George W., Peter Tugwell, Stacey L. Amorosi, Elliot Chartash, & Nishan Sengupta. (2004). Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Lara D. Veeken. 43(6). 712–718. 27 indexed citations
11.
Weinblatt, Michael E., Edward Keystone, Daniel E. Furst, et al.. (2003). Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis & Rheumatism. 48(1). 35–45. 1413 indexed citations breakdown →
12.
Hingorani, Ravi, J Monteiro, Robert G. Pergolizzi, et al.. (1995). CDR3 Length Restriction of T‐Cell Receptor β Chains in CD8+ T‐Cells of Rheumatoid Arthritis Patients. Annals of the New York Academy of Sciences. 756(1). 179–182. 8 indexed citations
13.
Jain, Rinku, Elliot Chartash, Myron Susin, & Richard Furie. (1994). Systemic lupus erythematosus complicated by thrombotic microangiopathy. Seminars in Arthritis and Rheumatism. 24(3). 173–182. 55 indexed citations
14.
Chartash, Elliot, et al.. (1992). Cardiac manifestations of the antiphospholipid syndrome. American Heart Journal. 124(5). 1331–1338. 81 indexed citations
15.
Chartash, Elliot, Mary K. Crow, & Steven Friedman. (1989). Biochemical basis of synergy between antigen and T-helper (Th) cell-mediated activation of resting human B cells.. Journal of Clinical Investigation. 84(5). 1410–1417. 3 indexed citations
16.
Chartash, Elliot, et al.. (1989). Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. The American Journal of Medicine. 86(4). 407–412. 110 indexed citations
17.
Chartash, Elliot, et al.. (1989). T helper cell-induced CD23 (BLAST-2) expression: An activation marker for the high density fraction of human B cells. Clinical Immunology and Immunopathology. 53(1). 99–112. 16 indexed citations
18.
Chartash, Elliot, Ayako Imai, M C Gershengorn, Mary K. Crow, & Steven Friedman. (1988). Direct human T helper cell-induced B cell activation is not mediated by inositol lipid hydrolysis.. The Journal of Immunology. 140(6). 1974–1981. 10 indexed citations
19.
Furie, Richard & Elliot Chartash. (1988). Tendon rupture in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 18(2). 127–133. 37 indexed citations
20.
Friedman, Steven, Juan Ángel Jover, Elliot Chartash, & Mary K. Crow. (1986). Antigen-specific, MHC nonrestricted T helper cell-induced B cell activation.. The Journal of Experimental Medicine. 164(5). 1773–1778. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Rubbert‐Roth Breakdown of academic impact, for papers by Maria Greenwald Breakdown of academic impact, for papers by Xavier Le Loët Breakdown of academic impact, for papers by Hans‐Peter Tony Breakdown of academic impact, for papers by Alain Cantagrel Breakdown of academic impact, for papers by C. Birbara Breakdown of academic impact, for papers by Raimón Sanmartí Breakdown of academic impact, for papers by Emma Alecock Breakdown of academic impact, for papers by Alejandro Balsa Breakdown of academic impact, for papers by Hideto Kameda
Rankless by CCL
2026